McKesson is cutting the pay of CEO Brian Tyler by $2.9 million because of the drug distributor's unsettled agreement to pay out of opioid litigation for $8.1 billion. He still made $14.8 million in cash and equity, The Washington Post reported June 11.
The distributor docked Mr. Tyler's pay after activist investors urged it to reflect its opioid settlements in executive pay appraisals.
McKesson is one of four drug companies in talks with states to resolve claims about their role in the opioid epidemic for a combined payout of more than $26 billion. It is the only one to decrease executive pay due to that settlement's expected costs.